Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Functional depletion of mahogunin by cytosolically exposed prion protein contributes to neurodegeneration.

Chakrabarti O, Hegde RS.

Cell. 2009 Jun 12;137(6):1136-47. doi: 10.1016/j.cell.2009.03.042.

2.

Mahogunin regulates fusion between amphisomes/MVBs and lysosomes via ubiquitination of TSG101.

Majumder P, Chakrabarti O.

Cell Death Dis. 2015 Nov 5;6:e1970. doi: 10.1038/cddis.2015.257.

3.

Cytoplasmic prion protein induces forebrain neurotoxicity.

Wang X, Bowers SL, Wang F, Pu XA, Nelson RJ, Ma J.

Biochim Biophys Acta. 2009 Jun;1792(6):555-63. doi: 10.1016/j.bbadis.2009.02.014. Epub 2009 Mar 10.

4.

Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function.

Lin DT, Jodoin J, Baril M, Goodyer CG, Leblanc AC.

Biochim Biophys Acta. 2008 Oct;1783(10):2001-12. doi: 10.1016/j.bbamcr.2008.05.022. Epub 2008 Jun 6.

5.

Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.

Silvius D, Pitstick R, Ahn M, Meishery D, Oehler A, Barsh GS, DeArmond SJ, Carlson GA, Gunn TM.

PLoS One. 2013;8(1):e55575. doi: 10.1371/journal.pone.0055575. Epub 2013 Jan 30.

6.

Cytosolic prion protein toxicity is independent of cellular prion protein expression and prion propagation.

Norstrom EM, Ciaccio MF, Rassbach B, Wollmann R, Mastrianni JA.

J Virol. 2007 Mar;81(6):2831-7. Epub 2006 Dec 20.

7.

Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein.

Stewart RS, Piccardo P, Ghetti B, Harris DA.

J Neurosci. 2005 Mar 30;25(13):3469-77.

8.

Manganese upregulates cellular prion protein and contributes to altered stabilization and proteolysis: relevance to role of metals in pathogenesis of prion disease.

Choi CJ, Anantharam V, Martin DP, Nicholson EM, Richt JA, Kanthasamy A, Kanthasamy AG.

Toxicol Sci. 2010 Jun;115(2):535-46. doi: 10.1093/toxsci/kfq049. Epub 2010 Feb 22.

9.

Prion topology and toxicity.

Aguzzi A, Steele AD.

Cell. 2009 Jun 12;137(6):994-6. doi: 10.1016/j.cell.2009.05.041.

10.

A transmembrane form of the prion protein in neurodegenerative disease.

Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR.

Science. 1998 Feb 6;279(5352):827-34.

11.

RML prions act through Mahogunin and Attractin-independent pathways.

Gunn TM, Carlson GA.

Prion. 2013 Jul-Aug;7(4):267-71. doi: 10.4161/pri.25054. Epub 2013 May 31.

12.

Prion-induced neuronal damage--the mechanisms of neuronal destruction in the subacute spongiform encephalopathies.

Giese A, Kretzschmar HA.

Curr Top Microbiol Immunol. 2001;253:203-17. Review.

PMID:
11417136
13.

Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP.

Rambold AS, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer KF, Tatzelt J.

Mol Biol Cell. 2006 Aug;17(8):3356-68. Epub 2006 May 17.

14.

Acute formation of protease-resistant prion protein does not always lead to persistent scrapie infection in vitro.

Vorberg I, Raines A, Priola SA.

J Biol Chem. 2004 Jul 9;279(28):29218-25. Epub 2004 May 7.

15.

Microdeletions within the hydrophobic core region of cellular prion protein alter its topology and metabolism.

Lutz J, Brabeck C, Niemann HH, Kloz U, Korth C, Lingappa VR, Bürkle A.

Biochem Biophys Res Commun. 2010 Mar 12;393(3):439-44. doi: 10.1016/j.bbrc.2010.02.015. Epub 2010 Feb 6.

PMID:
20138835
16.

Prion protein self-interactions: a gateway to novel therapeutic strategies?

Rigter A, Langeveld JP, van Zijderveld FG, Bossers A.

Vaccine. 2010 Nov 16;28(49):7810-23. doi: 10.1016/j.vaccine.2010.09.012. Epub 2010 Oct 20. Review.

PMID:
20932496
17.

Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.

Iraci N, Stincardini C, Barreca ML, Biasini E.

Virus Res. 2015 Sep 2;207:62-8. doi: 10.1016/j.virusres.2014.10.015. Epub 2014 Oct 23. Review.

PMID:
25456402
18.

Protection from cytosolic prion protein toxicity by modulation of protein translocation.

Rane NS, Yonkovich JL, Hegde RS.

EMBO J. 2004 Nov 24;23(23):4550-9. Epub 2004 Nov 4.

19.

Evolving views in prion glycosylation: functional and pathological implications.

Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O, Botti J.

Biochimie. 2003 Jan-Feb;85(1-2):33-45. Review.

PMID:
12765773
20.

Targeting prion proteins in neurodegenerative disease.

Gilch S, Krammer C, Schätzl HM.

Expert Opin Biol Ther. 2008 Jul;8(7):923-40. doi: 10.1517/14712598.8.7.923 . Review.

PMID:
18549323

Supplemental Content

Support Center